HEMOGENYX PHARMACEUTICALS PLC

Regulatory Filings • Jul 6, 2020

National Storage Mechanism | Additional information

RNS Number : 0575S

Hemogenyx Pharmaceuticals PLC

06 July 2020

6 July 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

New Corporate Video and Investor Webinar

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a new corporate video is available to view on the Company's website and can be accessed by following the link: 

https://youtu.be/LP95GWupyNA

In addition, the Company also announces that Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals will host a live investor webinar on 20 July 2020 at 16:00 UK time at which he will answer questions about the Company's current activities.  If you would like to register for the webinar, please follow this link:

https://us02web.zoom.us/meeting/register/tZIocuyrqj4pH9HRgZuobXLJdSDkRXUDFRDU

After registering, you will receive a confirmation email containing information about joining the meeting.

Please submit your questions in advance and not later than 17 July 2020 by emailing hemogenyx@hemogenyx.com.

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries	Tel: +1 (323) 646-3249
Lowell Goodman	lowell@corbomitecomms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRARAMBTMTBMTMM